vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and UPBOUND GROUP, INC. (UPBD). Click either name above to swap in a different company.
UPBOUND GROUP, INC. is the larger business by last-quarter revenue ($1.2B vs $598.7M, roughly 2.0× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 1.7%, a 39.2% gap on every dollar of revenue. On growth, UPBOUND GROUP, INC. posted the faster year-over-year revenue change (10.9% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $24.0M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 4.5%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Upbound Group, Inc. is a leading US provider of flexible lease-to-own solutions for consumer goods. It offers furniture, consumer electronics, home appliances, and accessories, catering to customers seeking accessible payment alternatives to traditional retail financing.
EXEL vs UPBD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $1.2B |
| Net Profit | $244.5M | $19.7M |
| Gross Margin | 95.6% | 49.0% |
| Operating Margin | 39.3% | 4.8% |
| Net Margin | 40.8% | 1.7% |
| Revenue YoY | 5.6% | 10.9% |
| Net Profit YoY | 74.8% | -36.3% |
| EPS (diluted) | $0.89 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $1.2B | ||
| Q3 25 | $568.3M | $1.2B | ||
| Q2 25 | $555.4M | $1.2B | ||
| Q1 25 | $566.8M | $1.2B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $539.5M | $1.1B | ||
| Q2 24 | $637.2M | $1.1B |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $19.7M | ||
| Q3 25 | $184.8M | $13.2M | ||
| Q2 25 | $159.6M | $15.5M | ||
| Q1 25 | $139.9M | $24.8M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | $118.0M | $30.9M | ||
| Q2 24 | $226.1M | $33.9M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 49.0% | ||
| Q3 25 | 96.6% | 48.3% | ||
| Q2 25 | 96.5% | 49.4% | ||
| Q1 25 | 96.5% | 46.8% | ||
| Q4 24 | — | 47.1% | ||
| Q3 24 | 96.8% | 47.8% | ||
| Q2 24 | 97.2% | 49.4% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 4.8% | ||
| Q3 25 | 37.6% | 4.5% | ||
| Q2 25 | 33.6% | 4.4% | ||
| Q1 25 | 28.8% | 5.3% | ||
| Q4 24 | — | 7.3% | ||
| Q3 24 | 25.2% | 6.6% | ||
| Q2 24 | 43.3% | 7.5% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 1.7% | ||
| Q3 25 | 32.5% | 1.1% | ||
| Q2 25 | 28.7% | 1.3% | ||
| Q1 25 | 24.7% | 2.1% | ||
| Q4 24 | — | 2.9% | ||
| Q3 24 | 21.9% | 2.9% | ||
| Q2 24 | 35.5% | 3.2% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $0.35 | ||
| Q3 25 | $0.65 | $0.22 | ||
| Q2 25 | $0.55 | $0.26 | ||
| Q1 25 | $0.47 | $0.42 | ||
| Q4 24 | — | $0.55 | ||
| Q3 24 | $0.40 | $0.55 | ||
| Q2 24 | $0.77 | $0.61 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $120.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $695.7M |
| Total Assets | $2.8B | $3.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $120.5M | ||
| Q3 25 | $791.1M | $107.0M | ||
| Q2 25 | $1.0B | $106.8M | ||
| Q1 25 | $1.1B | $107.3M | ||
| Q4 24 | — | $60.9M | ||
| Q3 24 | $1.2B | $85.1M | ||
| Q2 24 | $1.0B | $82.5M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $695.7M | ||
| Q3 25 | $2.0B | $687.3M | ||
| Q2 25 | $2.1B | $685.5M | ||
| Q1 25 | $2.2B | $679.2M | ||
| Q4 24 | — | $629.0M | ||
| Q3 24 | $2.3B | $611.8M | ||
| Q2 24 | $2.1B | $596.3M |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $3.3B | ||
| Q3 25 | $2.7B | $3.2B | ||
| Q2 25 | $2.8B | $3.1B | ||
| Q1 25 | $2.9B | $3.0B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | $3.0B | $2.6B | ||
| Q2 24 | $2.8B | $2.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $41.6M |
| Free Cash FlowOCF − Capex | $332.4M | $24.0M |
| FCF MarginFCF / Revenue | 55.5% | 2.0% |
| Capex IntensityCapex / Revenue | 0.2% | 1.5% |
| Cash ConversionOCF / Net Profit | 1.36× | 2.11× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $238.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $41.6M | ||
| Q3 25 | $49.0M | $118.4M | ||
| Q2 25 | $211.4M | $7.8M | ||
| Q1 25 | $240.3M | $137.7M | ||
| Q4 24 | — | $-61.9M | ||
| Q3 24 | $271.3M | $106.2M | ||
| Q2 24 | $119.5M | $15.0M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $24.0M | ||
| Q3 25 | $46.2M | $97.9M | ||
| Q2 25 | $208.5M | $-10.4M | ||
| Q1 25 | $236.3M | $127.2M | ||
| Q4 24 | — | $-74.0M | ||
| Q3 24 | $263.1M | $88.3M | ||
| Q2 24 | $113.0M | $613.0K |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 2.0% | ||
| Q3 25 | 8.1% | 8.4% | ||
| Q2 25 | 37.5% | -0.9% | ||
| Q1 25 | 41.7% | 10.8% | ||
| Q4 24 | — | -6.9% | ||
| Q3 24 | 48.8% | 8.3% | ||
| Q2 24 | 17.7% | 0.1% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 1.5% | ||
| Q3 25 | 0.5% | 1.8% | ||
| Q2 25 | 0.5% | 1.6% | ||
| Q1 25 | 0.7% | 0.9% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | 1.5% | 1.7% | ||
| Q2 24 | 1.0% | 1.3% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 2.11× | ||
| Q3 25 | 0.27× | 8.96× | ||
| Q2 25 | 1.32× | 0.50× | ||
| Q1 25 | 1.72× | 5.56× | ||
| Q4 24 | — | -2.00× | ||
| Q3 24 | 2.30× | 3.44× | ||
| Q2 24 | 0.53× | 0.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
UPBD
Segment breakdown not available.
